Loading clinical trials...

Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II) | Clinical Trials | Clareo Health

COMPLETED

Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)

Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics

NCT05550805•Qilu Hospital of Shandong University

View on ClinicalTrials.gov

Summary

To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Hospitalized patients with the diagnosis of any type of coronary artery disease;
•2. Age ≥18 years of age;
•3. Patient or guardian provided informed written consent.

Exclusion Criteria

•1. Prior surgery, trauma or clinically evident coagulopathic bleeding within the previous 2 weeks;
•2. Bipass population with missing follow-up records in Qilu Hospital emergency follow-up cohort.

Locations (1)

Yuguo Chen

Jinan, Shandong, China

Key Dates

Start Date

November 1, 2017

Primary Completion Date

March 1, 2022

Completion Date

March 1, 2022

Last Updated

May 31, 2025

Enrollment

5,822

ACTUAL participants

Conditions

Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease